• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

ME/CSF or long covid - similar organs are affected.

SWAlexander

Senior Member
Messages
1,942
There is only one substance that reaches all these organs – it is the BLOOD.
If our blood is contaminated or blogged by clots and micro-clots none of these organs are function properly.

Which organ could have the biggest impact on our blood?
I would say: liver
1640163831136.png
 
Last edited:

SWAlexander

Senior Member
Messages
1,942
SARS-CoV-2 infection and persistence throughout the human body and brain
Abstract:
COVID-19 is known to cause multi-organ dysfunction1-3 in acute infection, with prolonged symptoms experienced by some patients, termed Post-Acute Sequelae of SARS-CoV-2 (PASC)4-5. However, the burden of infection outside the respiratory tract and time to viral clearance is not well characterized, particularly in the brain3,6-14. We performed complete autopsies on 44 patients with COVID-19 to map and quantify SARS-CoV-2 distribution, replication, and cell-type specificity across the human body, including brain, from acute infection through over seven months following symptom onset. We show that SARS-CoV-2 is widely distributed, even among patients who died with asymptomatic to mild COVID-19, and that virus replication is present in multiple extrapulmonary tissues early in infection. Further, we detected SARS-CoV-2 RNA in multiple anatomic sites, including regions throughout the brain, for up to 230 days following symptom onset. Despite extensive distribution of SARS-CoV-2 in the body, we observed a paucity of inflammation or direct viral cytopathology outside of the lungs. Our data prove that SARS-CoV-2 causes systemic infection and can persist in the body for months.
https://www.researchsquare.com/article/rs-1139035/v1

https://twitter.com/microbeminded2/status/1473721448342687754
Amy Proal, PhD
@microbeminded2

7/ In addition to ddPCR, the team used ISH to identify SARS-CoV-2 #spike RNA across selected early, mid + late cases. Spike RNA was found in #neurons, glia and ependyma, as well as endothelium of vessels across all lobes of the brain of early, mid, and late cases
8/ Within the cerebellum specifically, neurons, Purkinje cells, and endothelium of #vasculature also contained spike protein via IHC
https://twitter.com/microbeminded2/status/1473723279873617923/photo/1
 
Last edited:

SWAlexander

Senior Member
Messages
1,942
SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation
https://elifesciences.org/articles/...utm_medium=social&utm_campaign=organic_12Days
Abstract
Many enveloped viruses induce multinucleated cells (syncytia), reflective of membrane fusion events caused by the same machinery that underlies viral entry. These syncytia are thought to facilitate replication and evasion of the host immune response. Here, we report that co-culture of human cells expressing the receptor ACE2 with cells expressing SARS-CoV-2 spike, results in synapse-like intercellular contacts that initiate cell-cell fusion, producing syncytia resembling those we identify in lungs of COVID-19 patients. To assess the mechanism of spike/ACE2-driven membrane fusion, we developed a microscopy-based, cell-cell fusion assay to screen ~6000 drugs and >30 spike variants. Together with quantitative cell biology approaches, the screen reveals an essential role for biophysical aspects of the membrane, particularly cholesterol-rich regions, in spike-mediated fusion, which extends to replication-competent SARS-CoV-2 isolates. Our findings potentially provide a molecular basis for positive outcomes reported in COVID-19 patients taking statins and suggest new strategies for therapeutics targeting the membrane of SARS-CoV-2 and other fusogenic viruses.